A pivotal randomized, controlled, multi-center study of LJPC-401 in beta thalassemia patients suffering from iron overload

Trial Profile

A pivotal randomized, controlled, multi-center study of LJPC-401 in beta thalassemia patients suffering from iron overload

Planning
Phase of Trial: Phase III

Latest Information Update: 01 Mar 2017

At a glance

  • Drugs Hepcidin (Primary)
  • Indications Iron overload
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Mar 2017 Planned initiation date changed to 1 Jun 2017.
    • 22 Sep 2016 New trial record
    • 07 Sep 2016 According to a La Jolla Pharmaceutical Company media release, the company has reached agreement with the European Medicines Agency (EMA) on the design of this pivotal study of LJPC-401.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top